Liftstream is an executive search recruitment company in the life sciences sector
Biotech M&A Continues to Climb the Curve
The trajectory of biotech M&A has been steep in 2015, so the $7.2bn acquisition of Receptos by oncology powerhouse Celgene, increases the gradient even further. This deal came out of left field, especially as commentators were still raking over the sizable partnering deal Celgene has just cemented with Juno Therapeutics in immuno-oncology.
Merck announces collaboration with Advaxis
Authored by James Sheppard
ADC Therapeutics executives on fast track with funding and partners
Authored by James Sheppard
AstraZeneca makes play in ADC market
Authored by James Sheppard
AstraZeneca Binds to biologics for new strategy Horizon
Authored by James Sheppard
David Motts’ NEA weighs in on rare diseases
Authored by Karl Simpson
Prosensa & GSK pool resources to drive Drisapersen in Duchenne
Authored by Karl Simpson
Soriot to apply therapy to AstraZeneca
On 26th of April 2012 David Brennan stepped down as AstraZeneca’s CEO after 6 years in the job. David Brennan had risen through the ranks at AstraZeneca first at Astra and later after the merger with ICI spin-off Zeneca. Brennan had been criticised by investors for failing to sure up the companies pipeline as a wave of patents expired. Yet, when Brennan announced he was leaving, AstraZeneca’s share price fell dramatically and took nearly two months to recover.